The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Mylan Pharmaceuticals Inc's Triamcinolone Acetonide Ointment, Lupin said in a statement.
PTI
@moneycontrolcom
Drug maker Lupin said on Monday it has received an approval from the US health regulator to market its Triamcinolone Acetonide ointment, used to treat skin conditions, in the US market.
The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Mylan Pharmaceuticals Inc's Triamcinolone Acetonide Ointment, Lupin said in a statement.
As per the IQVIA MAT June 2018 sales data, Triamcinolone Acetonide Ointment had annual sales of around USD 25.7 million in the US.
First Published on Oct 22, 2018 04:36 pm
